GLAND.NS Profit & Loss
Gland Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:36
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹3,624.60 Cr. | ₹5,664.72 Cr. | ₹5,616.50 Cr. | ₹6,430.65 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹240.46 Cr. | ₹170.24 Cr. | ₹213.61 Cr. | ₹316.33 Cr. | OtherIncome |
| Total Income | ₹3,865.06 Cr. | ₹5,834.96 Cr. | ₹5,830.11 Cr. | ₹6,746.98 Cr. | Income |
| Cost of Materials Consumed | ₹1,716.75 Cr. | ₹2,022.14 Cr. | ₹1,972.48 Cr. | ₹2,239.75 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹15.59 Cr. | ₹23.07 Cr. | ₹14.49 Cr. | ₹6.60 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-46.92 Cr. | ₹127.89 Cr. | ₹103.41 Cr. | ₹-3.42 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹403.26 Cr. | ₹1,256.89 Cr. | ₹1,401.56 Cr. | ₹1,628.84 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹7.45 Cr. | ₹26.20 Cr. | ₹42.00 Cr. | ₹33.28 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹146.74 Cr. | ₹344.57 Cr. | ₹377.87 Cr. | ₹423.67 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹511.15 Cr. | ₹901.67 Cr. | ₹855.64 Cr. | ₹929.34 Cr. | OtherExpenses |
| Total Expenses | ₹2,754.02 Cr. | ₹4,702.41 Cr. | ₹4,767.45 Cr. | ₹5,258.05 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹1,111.04 Cr. | ₹1,132.54 Cr. | ₹1,062.66 Cr. | ₹1,488.93 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹-56.46 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹-24.35 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹1,054.58 Cr. | ₹1,132.54 Cr. | ₹1,062.66 Cr. | ₹1,464.58 Cr. | ProfitBeforeTax |
| Tax Expense | ₹273.54 Cr. | ₹360.08 Cr. | ₹364.13 Cr. | ₹437.26 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹781.04 Cr. | ₹772.46 Cr. | ₹698.53 Cr. | ₹1,027.32 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹781.04 Cr. | ₹772.46 Cr. | ₹698.53 Cr. | ₹1,027.32 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹47.44 | ₹46.90 | ₹42.40 | ₹62.35 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹47.43 | ₹46.89 | ₹42.40 | ₹62.28 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from GLAND.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).